ESMO verdict on next generation sequencing

New guidelines give a thumbs down for routine use of next generation sequencing (NGS) in common cancers such as breast cancer – but a thumbs up in other tumours types such as advanced non-squamous NSCLC, prostate cancer, ovarian cancer and cholangiocarcinoma. The European Society for Medical Oncology (ESMO) recommendations for the use of next generation ...

Already a member?

Login to keep reading.

© 2021 the limbic